ArticleCurrent oncology (Toronto, Ont.)2015

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

N W D Lamond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.